Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 50 shares, a decrease of 99.8% from the May 14th total of 23,016 shares. Based on an average daily volume of 1,489 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Innate Pharma Stock Performance

Shares of IPHYF stock remained flat at $1.65 during mid-day trading on Thursday. Innate Pharma has a twelve month low of $1.37 and a twelve month high of $2.25. The stock’s 50-day simple moving average is $1.64 and its two-hundred day simple moving average is $1.92.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.